Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib for Recurrent or Refractory Pediatric Low Grade Glioma
NCT01089101Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2010
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in low-grade glioma (LGG), pilocytic astrocytoma (PA), Visual pathway glioma (OPG), sponsored by National Cancer Institute. Started Jul 2010; status: active, not recruiting.
02
Drugs
selumetinib
03
Conditions
low-grade glioma (LGG)pilocytic astrocytoma (PA)Visual pathway glioma (OPG)
Beyond the preview
Go deeper on NCT01089101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01089101.